OverviewChartNewsTraderScreen

UC TUR.WAR.OP.END. 1AE/  DE000HD1DL54  /

gettex Zertifikate
31/07/2024  21:46:43 Chg.+0.750 Bid21:59:54 Ask21:59:54 Underlying Strike price Expiration date Option type
23.310EUR +3.32% 23.110
Bid Size: 200		 23.620
Ask Size: 200		 Argen X NV 241.1587 - 31/12/2078 Call
GlobeNewswire 25/06 argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 P...
GlobeNewswire 21/06 argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropat...
GlobeNewswire 17/06 argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcomi...
GlobeNewswire 13/06 Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
GlobeNewswire 04/06 argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire 09/05 argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 07/05 argenx announces results of Annual General Meeting of Shareholders
GlobeNewswire 07/05 argenx to Present at BofA Securities 2024 Health Care Conference
GlobeNewswire 02/05 argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
GlobeNewswire 16/04 argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Pa...
GlobeNewswire 27/03 argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
GlobeNewswire 26/03 argenx Announces Annual General Meeting of Shareholders on May 7, 2024
GlobeNewswire 26/03 argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thr...
GlobeNewswire 07/03 argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of ...
GlobeNewswire 29/02 argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
GlobeNewswire 26/02 argenx to Present at Upcoming Investor Conferences
GlobeNewswire 22/02 argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29,...
GlobeNewswire 20/02 argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review f...
GlobeNewswire 14/02 Genmab Publishes 2023 Annual Report
GlobeNewswire 18/01 argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcu...
GlobeNewswire 08/01 argenx Highlights 2024 Strategic Priorities
GlobeNewswire 02/01 argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 07/12/2023 TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commerci...
GlobeNewswire 28/11/2023 argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocyt...
GlobeNewswire 16/11/2023 argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Gene...